Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Ani Pharmaceuticals (ANIP) over the last 12 years, with Q3 2025 value amounting to $340000.0.

  • Ani Pharmaceuticals' Amortization of Deferred Charges rose 18099.17% to $340000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 2480.18%. This contributed to the annual value of $642000.0 for FY2024, which is 8363.08% down from last year.
  • Ani Pharmaceuticals' Amortization of Deferred Charges amounted to $340000.0 in Q3 2025, which was up 18099.17% from $341000.0 recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Amortization of Deferred Charges registered a high of $998000.0 during Q4 2022, and its lowest value of $102000.0 during Q1 2024.
  • In the last 5 years, Ani Pharmaceuticals' Amortization of Deferred Charges had a median value of $590000.0 in 2022 and averaged $575631.6.
  • Per our database at Business Quant, Ani Pharmaceuticals' Amortization of Deferred Charges plummeted by 8966.57% in 2024 and then surged by 21764.71% in 2025.
  • Ani Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $794000.0 in 2021, then grew by 25.69% to $998000.0 in 2022, then dropped by 4.61% to $952000.0 in 2023, then plummeted by 66.07% to $323000.0 in 2024, then increased by 5.26% to $340000.0 in 2025.
  • Its Amortization of Deferred Charges was $340000.0 in Q3 2025, compared to $341000.0 in Q2 2025 and $324000.0 in Q1 2025.